FDA Inspections and Outcomes for Oral Solid Dosage (OSD) Manufacturing Facilities

Posted 14 July 2017 By Sharry Arora

placeholder+image The article discusses various types of current Good Manufacturing Practice (CGMP) inspections conducted by the US Food and Drug Administration (FDA) at oral solid dosage forms manufacturing facilities. It also elaborates on types of inspections, approaches to investigations, limitations of these inspections and major inspection outcomes in the event of deficiencies, including 483s, Warning Letters and Establishment Investigation Reports (EIRs).

Share this article:

Categories: Drugs, Compliance, Manufacturing, Features, US, FDA

Tags: Oral Solid Dosage, OSD, Inspections

Regulatory Exchange: Latest Updates From the Community